Quietly replacing the old way: customers are switching to the company from an entrenched alternative, and the switching
The model's full reasoning — Q3 2018 call → NO我们根据提供的财报电话会议记录来判断管理层是否描述了客户正在从既有替代品转向公司产品,且这种转换仍处于早期阶段。 在记录中,管理层讨论了TIBSOVO(ivosidenib)的上市情况。Steve Hoerter提到:“Since our launch in July, our team of senior hematology sales consultants has had approximately 2,000 customer interactions... Increasing testing rates of the IDH mutation is a key strategic imperative... we’re encouraged with the steady growth... approximately 80% of physicians were testing their patients for the IDH1 and IDH2 mutations.” 这里提到测试率增长,但并未明确说客户从其他产品转向TIBSOVO。管理层提到“physician awareness of TIBSOVO is already above 90%”,但未提及替代其他产品。 关于IDHIFA(enasidenib)是Celgene的产品,Agios有合作,但TIBSOVO是Agios自己的。管理层没有说客户从IDHIFA转向TIBSOVO,而是说两者都是IDH抑制剂,但IDH1和IDH2不同。实际上,TIBSOVO是IDH1抑制剂,IDHIFA是IDH2抑制剂,它们针对不同突变,并非直接替代关系。 管理层提到“we are rewriting the textbooks on treating IDH mutant AML”,但未具体描述客户从旧方法转向新方法。关于测试率,管理层说“Increasing testing rates of the IDH mutation is a key strategic imperative”,但这是关于测试,不是关于治疗选择。 在回答中,管理层没有明确说客户正在从既有替代品转向他们的产品。他们只是说销售增长,但未提及替代其他产品。因此,不符合“switching”的定义。 此外,管理层提到“we estimate over 100 unique prescribers have written a prescription for our medicine”,但未说这些处方来自之前使用其他产品的医生。 因此,答案应为NO。
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| CRGO | Freightos Limited | Q1 2024 | 2024-05-20 | C+ |
| IFS | Intercorp Financial Services Inc. | Q1 2024 | 2024-05-14 | C+ |
| NICE | NICE Ltd. | Q4 2023 | 2024-02-22 | B+ |
| APPS | Digital Turbine, Inc. | Q1 2024 | 2023-08-08 | D |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| MBLY | Mobileye Global Inc. | Q2 2023 | 2023-07-28 | B+ |
| IMAX | IMAX Corporation | Q2 2023 | 2023-07-26 | B+ |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| TOST | Toast, Inc. | Q4 2022 | 2023-02-16 | C+ |
| BLZE | Backblaze, Inc. | Q3 2022 | 2022-11-11 | D |
| SIBN | SI-BONE, Inc. | Q3 2022 | 2022-11-07 | C+ |
| TMCI | Treace Medical Concepts, Inc. | Q2 2022 | 2022-08-13 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| BIG | Big Lots, Inc. | Q1 2022 | 2022-05-27 | F |
| FLYW | Flywire Corporation | Q1 2022 | 2022-05-14 | B+ |
| ZVIA | Zevia PBC | Q1 2022 | 2022-05-12 | B |
| IRTC | iRhythm Technologies, Inc. | Q1 2022 | 2022-05-07 | C+ |
| RELY | Remitly Global, Inc. | Q4 2021 | 2022-03-02 | B |
| GTES | Gates Industrial Corporation plc | Q4 2021 | 2022-02-07 | C+ |
| RNW | ReNew Energy Global Plc | Q2 2022 | 2021-11-18 | C |
| ILMN | Illumina, Inc. | Q1 2018 | 2018-04-24 | A |
| INST | Instructure's | Q4 2017 | 2018-02-12 | B+ |
| HOLX | Hologic, Inc. | Q4 2017 | 2017-11-08 | D |
| BLKB | Blackbaud, Inc. | Q1 2017 | 2017-05-02 | B+ |
| EVBN | Evans Bancorp, Inc. | Q4 2016 | 2017-02-06 | B+ |
| BDC | Belden Inc. | Q4 2016 | 2017-02-02 | B |
BLKB · Q1 2017 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES Management describes customers switching from entrenched alternatives (legacy hardware systems, older Raiser's Edge versions, standalone point solutions) to Blackbaud's cloud solutions like NXT, with examples of recent replacements and migrations already occurring. They also note that much of the potential remains, as the installed base of legacy methods is still large 25% of subscription revenue, and they describe the opportunity as "really early days" with substantial distance left to run. This fits the criteria of a present-tense substitution pattern in the market, not just future hope. The high retention on their own base (93%) combined with declining maintenance revenue shows the shift is active and ongoing, while new wins against competitors and legacy alternatives are happening now. The TAM of $7 billion with hundreds of thousands of addressable customers reinforces that switching is early-stage relative to the total opportunity. The answer is YES. The question is answered with YES. The question is answered with YES.
BLZE · Q3 2022 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES The transcript shows management describing current customer switches from entrenched alternatives (AWS for urlscan.io; Synology NAS/on-prem for Fiture; broader AWS and on-prem users), with these as real, ongoing patterns. They explicitly note that much of the potential remains ("so much of the world's data is still on-premises" and "customers that are inside of AWS and others"), confirming the substitution is early-stage relative to the large installed base. This is conveyed directly in Gleb's responses as a present-tense reality, not merely anticipated. The two examples plus the broader opportunity framing establish a coherent substitution underway, with the company being substituted in. The investor question on percentages and Gleb's reply reinforce the pattern without contradicting the current movement. No single-event or future-only framing applies here. Thus, both conditions are met.
APPS · Q1 2024 → YESThe question is: Does management describe that customers are currently SWITCHING TO THE COMPANY FROM AN ENTRENCHED ALTERNATIVE THEY PREVIOUSLY RELIED ON, and that this switching is still in its early ...YES The transcript shows management describing customers shifting from Apple/Google app stores to DT Hub and SingleTap-enabled alternative distribution as an ongoing, early-stage substitution. Bill Stone notes the company has already launched DT Hub with four U.S. operators and is generating revenue today, while highlighting "increasing pressure on the duopoly" and 5 monetization ways for SingleTap that enable publishers to direct-download apps outside traditional stores. He explicitly calls it "very early days and not yet material to our overall results" and "early innings," confirming the installed base of the old way remains large and the switch is just beginning with incremental RPD gains from devices engaging the new platform. This meets the criteria of a present-tense substitution underway, with the company positioned as the alternative being adopted.